Polaryx Therapeutics (PLYX) Shares Outstanding (2024 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Shares Outstanding (Entity) of $47.3 million for Q1 2026, up 5.05% year-over-year from $45.1 million in Q1 2025, and little changed quarter-over-quarter from $47.3 million in Q4 2025.
Polaryx Therapeutics (PLYX) Shares Outstanding (2024 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Shares Outstanding (Entity) for 3 consecutive years, with $47.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 5.05% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 5.05% YoY), while the FY2025 annual figure was $47.3 million, up 38.43% from the prior year.
- Shares Outstanding (Entity) held at $47.3 million in Q1 2026 per PLYX's latest filing, from $47.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $47.3 million in Q4 2025 and bottomed at $34.2 million in Q4 2024.
- Historically, Shares Outstanding (Entity) has averaged $43.5 million across 3 years, with a median of $46.2 million in 2025.
- Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) jumped 38.43% — and 2026, when it gained 5.05%.
- Polaryx Therapeutics' Shares Outstanding (Entity) stood at $34.2 million in 2024, then surged by 38.43% to $47.3 million in 2025, then changed by 0.0% to $47.3 million in 2026.
- Business Quant data shows PLYX's Shares Outstanding (Entity) at $47.3 million in Q1 2026, $47.3 million in Q4 2025, and $45.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Polaryx Therapeutics | 99.45 Mn | 87.91 Mn | - | 48.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.28 Mn |
| Mar 31, 2026 | 47.22 Mn |
| Dec 31, 2025 | 45.42 Mn |
| Mar 31, 2025 | 44.34 Mn |
| Dec 31, 2024 | 34.20 Mn |